Hospital
Ssm-Sluh INC
Ssm-Sluh INC was paid $20.65M by Medicaid between Jan 2018 and Dec 2024, across 165 billing codes. Its largest line is X4011, State-specific procedure code — 35% of everything it billed.
33Billing provider infoSSM-SLUH INC
SAINT LOUIS, MO 63104
SAINT LOUIS, MO 63104
33aNPI1942685920assigned 07/20/2015
33bProvider typeGeneral Acute Care Hospital
28Total paid$20.65M
24GClaims256,976
24DCodes billed165
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Missouri
Rank by total paid#18 of 74
Median peer was paid$4.44M
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 33,189 | $4.53M | |
| 2019 | 42,401 | $3.45M | |
| 2020 | 26,091 | $2.80M | |
| 2021 | 32,740 | $2.13M | |
| 2022 | 38,442 | $2.31M | |
| 2023 | 45,353 | $2.81M | |
| 2024incomplete | 38,760 | $2.62M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| X4011 | State-specific procedure code | 35% | 17,979 | 16,483 | $7.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 15,576 | 14,140 | $3.04M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.3% | 19,867 | 17,548 | $1.30M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.7% | 49,131 | 40,053 | $1.17M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 3,779 | 3,304 | $1.10M |
| 80053 | Comprehensive metabolic panel | 4.6% | 42,194 | 34,614 | $946K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.6% | 4,840 | 4,424 | $743K |
| X4014 | 3.5% | 1,485 | 1,432 | $725K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.7% | 11,167 | 9,954 | $548K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 3,411 | 3,028 | $364K |
| X4006 | 1.7% | 1,055 | 945 | $342K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 5,902 | 5,004 | $266K |
153 more codes
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 1.2% | 418 | $240K |
| X4003 | 1.0% | 3,442 | $212K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,795 | $190K |
| 81001 | <1% | 4,444 | $180K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,797 | $160K |
| 20610 | <1% | 3,371 | $149K | |
| G0378 | Hospital observation service, per hour | <1% | 390 | $148K |
| 84484 | <1% | 7,178 | $145K | |
| Y7506 | <1% | 694 | $144K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,514 | $127K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,873 | $114K |
| 81025 | <1% | 844 | $91K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 974 | $87K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,420 | $86K |
| J3490 | Unclassified drugs | <1% | 3,587 | $67K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,557 | $63K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,276 | $56K |
| 85610 | <1% | 1,996 | $30K | |
| 83690 | <1% | 1,218 | $28K | |
| 0240U | <1% | 308 | $27K | |
| 73610 | <1% | 708 | $27K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 425 | $26K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,359 | $25K |
| 84702 | <1% | 2,130 | $25K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 181 | $24K |
| 73630 | <1% | 583 | $22K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 217 | $21K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 768 | $20K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 417 | $20K |
| 80050 | General health panel | <1% | 44 | $18K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 302 | $15K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 466 | $12K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 159 | $11K |
| 73564 | <1% | 381 | $11K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,790 | $11K |
| 92134 | <1% | 396 | $11K | |
| 73560 | <1% | 163 | $11K | |
| 97162 | <1% | 83 | $10K | |
| 73130 | <1% | 707 | $10K | |
| 20611 | <1% | 101 | $9K | |
| 92083 | <1% | 240 | $9K | |
| 87522 | Neg quan hep c or qual rna | <1% | 255 | $9K |
| 72100 | <1% | 382 | $8K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 205 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 194 | $7K |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 68 | $7K |
| 72040 | <1% | 365 | $7K | |
| 83735 | <1% | 2,543 | $6K | |
| 83880 | <1% | 245 | $6K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 82 | $5K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 65 | $5K |
| 73521 | <1% | 91 | $5K | |
| 82550 | <1% | 297 | $5K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 34 | $5K |
| 82553 | <1% | 41 | $5K | |
| 82962 | <1% | 431 | $4K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 357 | $4K |
| 73502 | <1% | 173 | $4K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 42 | $4K |
| 81003 | <1% | 232 | $4K | |
| 86235 | <1% | 1,238 | $3K | |
| 73030 | <1% | 182 | $3K | |
| 91010 | <1% | 13 | $3K | |
| 72082 | <1% | 117 | $3K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 27 | $3K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 47 | $3K |
| 73110 | <1% | 198 | $3K | |
| 0001A | <1% | 160 | $3K | |
| 82805 | <1% | 33 | $2K | |
| 0002A | <1% | 145 | $2K | |
| 77336 | <1% | 47 | $2K | |
| 94726 | <1% | 15 | $2K | |
| 92202 | <1% | 158 | $2K | |
| 73562 | <1% | 154 | $2K | |
| 86038 | <1% | 585 | $2K | |
| 86832 | <1% | 19 | $2K | |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 14 | $2K |
| 94060 | <1% | 15 | $2K | |
| 91200 | <1% | 42 | $2K | |
| 86833 | <1% | 19 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 93 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 100 | $2K |
| 83605 | <1% | 164 | $1K | |
| 77334 | <1% | 18 | $1K | |
| 73523 | <1% | 17 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 66 | $1K |
| 72110 | <1% | 47 | $1K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 397 | $1K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 53 | $1K |
| 86256 | <1% | 182 | $1K | |
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | <1% | 29 | $859.44 |
| 84100 | <1% | 768 | $852.37 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 32 | $838.43 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 35 | $815.76 |
| 92133 | <1% | 29 | $741.73 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 346 | $732.49 |
| 72050 | <1% | 27 | $691.21 | |
| 86140 | <1% | 1,174 | $633.54 | |
| 86803 | <1% | 210 | $606.51 | |
| 86480 | <1% | 24 | $605.38 | |
| 83970 | <1% | 42 | $571.96 | |
| 86900 | <1% | 98 | $548.31 | |
| 82607 | <1% | 302 | $529.04 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 702 | $505.40 |
| 83516 | <1% | 352 | $484.49 | |
| 83615 | <1% | 696 | $460.50 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 12 | $440.60 |
| 85652 | <1% | 1,214 | $396.66 | |
| 85027 | <1% | 284 | $341.01 | |
| 86850 | <1% | 98 | $335.91 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 29 | $275.00 |
| 84439 | <1% | 585 | $273.59 | |
| 86160 | <1% | 206 | $268.43 | |
| 87340 | <1% | 284 | $261.64 | |
| 80061 | Lipid panel | <1% | 304 | $245.30 |
| 92025 | <1% | 13 | $220.32 | |
| 51798 | <1% | 14 | $201.60 | |
| 82728 | <1% | 432 | $186.67 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 330 | $185.53 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $181.10 |
| 86901 | <1% | 81 | $179.94 | |
| 84466 | <1% | 205 | $172.68 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 27 | $171.68 |
| 86200 | <1% | 77 | $162.25 | |
| 82784 | <1% | 127 | $152.82 | |
| 82746 | <1% | 142 | $149.97 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,027 | $119.39 |
| 83540 | <1% | 271 | $116.33 | |
| 82570 | <1% | 317 | $114.67 | |
| 86704 | <1% | 100 | $112.63 | |
| 72170 | <1% | 44 | $101.19 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 14 | $89.04 |
| 85730 | <1% | 112 | $74.46 | |
| 82085 | <1% | 123 | $60.26 | |
| 86706 | <1% | 46 | $58.65 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 335 | $56.36 |
| 86431 | <1% | 138 | $40.54 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 75 | $27.55 |
| 84550 | <1% | 160 | $17.34 | |
| 84165 | <1% | 26 | $15.78 | |
| 86225 | <1% | 18 | $12.98 | |
| V2632 | Posterior chamber intraocular lens | <1% | 285 | $10.32 |
| 82043 | <1% | 54 | $6.05 | |
| 84156 | <1% | 42 | $1.15 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 78 | $0.55 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 52 | $0.02 |
| A9270 | Non-covered item or service | 0% | 304 | $0.00 |
| 99070 | 0% | 237 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 20 | $0.00 |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 47 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 33 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 55 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 50 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCOTT, STEVEN (PRESIDENT)
Parent organizationSSM HEALTH CARE CORPORATION
| Provider | Location | Paid |
|---|---|---|
| Ministry Home Care, LLC. | Neenah, WI | $1.54M |
| Ministry Home Care, LLC. | Neenah, WI | $833K |
| Ministry Home Care, LLC. | Marshfield, WI | $178K |
| Phoenix Emergency Solutions of Fletcher PLLC | Hendersonville, NC | $164K |
| Wheaton Franciscan Home Health & Hospice, LLC | Milwaukee, WI | $43K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.